The International journal on drug policyFeb 19, 2026

Unclear rules and challenges in managing psilocybin mushrooms in Brazil

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗

Updated Feb 20, 2026

Abstract

The legal status of psilocybin mushrooms in Brazil remains ambiguous.

Regulatory uncertainty around psilocybin mushrooms is linked to broader debates in legal, drug policy, public health, and Indigenous rights.
A future regulatory approach to psilocybin may require integrating scientific evidence, Indigenous knowledge, and ethical governance.
Indigenous leadership in decision-making is essential for protecting traditional knowledge and aligning with international frameworks.
The lack of a coherent regulatory framework in Brazil contributes to legal uncertainty and inconsistent enforcement.
There is a call for formal deliberative spaces by regulatory bodies to create culturally sensitive and evidence-based psilocybin policies.

Simplified

The legal status of psilocybin mushrooms in Brazil remains ambiguous, despite increasing global scientific and public interest in their therapeutic and ceremonial use. This commentary examines the regulatory uncertainty surrounding psilocybin mushrooms in Brazil and situates the debate within broader legal, drug policy, public health, and Indigenous rights discussions. Building on academic literature, media reports, jurisprudence, and insights drawn from the regulatory experience surrounding ayahuasca, our commentary argues that any future coherent approach to psilocybin regulation would need to integrate scientific evidence, Indigenous knowledge, and ethical governance. We underscore the importance of regulatory mechanisms that ensure Indigenous leadership in decision-making and protect traditional knowledge, consistent with international frameworks such as the World Health Organization's Global Traditional Medicine Strategy and the United Nations Declaration on the Rights of Indigenous Peoples. Despite the growing international momentum toward psychedelic reform, the absence of a coherent framework in Brazil continues to generate legal uncertainty and arbitrary enforcement. Accordingly, our reflection points to the need to open formal deliberative spaces by regulatory bodies, particularly the Brazilian Health Regulatory Agency (ANVISA) and the National Drug Policy Council (CONAD), to develop evidence-based, culturally sensitive, and constitutionally consistent policies for psilocybin regulation in Brazil.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

PubMed

Unclear rules and challenges in managing psilocybin mushrooms in Brazil

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the psychedelic science brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the psychedelic science brief